GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PolyPeptide Group AG (XSWX:PPGN) » Definitions » Inventories, Finished Goods

PolyPeptide Group AG (XSWX:PPGN) Inventories, Finished Goods : CHF18.2 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is PolyPeptide Group AG Inventories, Finished Goods?

PolyPeptide Group AG's quarterly finished goods declined from Dec. 2022 (CHF31.8 Mil) to Jun. 2023 (CHF0.0 Mil) but then increased from Jun. 2023 (CHF0.0 Mil) to Dec. 2023 (CHF18.2 Mil).

PolyPeptide Group AG's annual finished goods increased from Dec. 2021 (CHF24.0 Mil) to Dec. 2022 (CHF31.8 Mil) but then declined from Dec. 2022 (CHF31.8 Mil) to Dec. 2023 (CHF18.2 Mil).


PolyPeptide Group AG Inventories, Finished Goods Historical Data

The historical data trend for PolyPeptide Group AG's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPeptide Group AG Inventories, Finished Goods Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial 20.61 20.59 23.97 31.80 18.22

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.97 - 31.80 - 18.22

PolyPeptide Group AG Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


PolyPeptide Group AG (XSWX:PPGN) Business Description

Traded in Other Exchanges
Address
Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives a majority of its revenue from Europe and Asia.

PolyPeptide Group AG (XSWX:PPGN) Headlines

No Headlines